Comparative Pharmacology
Head-to-head clinical analysis: BALVERSA versus TRUSELTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALVERSA versus TRUSELTIQ.
BALVERSA vs TRUSELTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FGFR kinase inhibitor; binds to and inhibits FGFR1-4, reducing phosphorylation and downstream signaling.
TRUSELTIQ (infigratinib) is a fibroblast growth factor receptor (FGFR) inhibitor that binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby blocking FGFR-mediated signal transduction pathways, including STAT, MAPK, and PI3K/AKT, leading to reduced tumor cell proliferation and angiogenesis.
8 mg orally once daily, with or without food, for adults.
600 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 17 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 11 hours (range 6.1–19.8 hours), supporting twice-daily dosing.
Primarily metabolized, with 69% of dose recovered in feces (19% unchanged) and 19% in urine (1% unchanged).
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 86% of the administered dose, while renal excretion accounts for about 12%.
Category C
Category C
FGFR Inhibitor
FGFR Inhibitor